318 related articles for article (PubMed ID: 23732713)
1. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
Anderson DR; Dunbar MJ; Bohm ER; Belzile E; Kahn SR; Zukor D; Fisher W; Gofton W; Gross P; Pelet S; Crowther M; MacDonald S; Kim P; Pleasance S; Davis N; Andreou P; Wells P; Kovacs M; Rodger MA; Ramsay T; Carrier M; Vendittoli PA
Ann Intern Med; 2013 Jun; 158(11):800-6. PubMed ID: 23732713
[TBL] [Abstract][Full Text] [Related]
2. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
3. A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty.
Intermountain Joint Replacement Center Writing Committee
J Arthroplasty; 2012 Jan; 27(1):1-9.e2. PubMed ID: 21621959
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty].
Tian H; Song F; Zhang K; Liu Y
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(47):3349-52. PubMed ID: 18478950
[TBL] [Abstract][Full Text] [Related]
5. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
6. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
[TBL] [Abstract][Full Text] [Related]
7. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
8. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
9. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.
Dager WE
Ann Pharmacother; 2012 Jan; 46(1):79-88. PubMed ID: 22202495
[TBL] [Abstract][Full Text] [Related]
10. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
11. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Bauersachs RM; Dudenhausen J; Faridi A; Fischer T; Fung S; Geisen U; Harenberg J; Herchenhan E; Keller F; Kemkes-Matthes B; Schinzel H; Spannagl M; Thaler CJ;
Thromb Haemost; 2007 Dec; 98(6):1237-45. PubMed ID: 18064320
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
Eriksson BI; Friedman RJ
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
[TBL] [Abstract][Full Text] [Related]
14. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
[TBL] [Abstract][Full Text] [Related]
15. DVT prophylaxis: better living through chemistry: affirms.
Pellegrini VD
Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
17. A mobile compression device compared with low-molecular-weight heparin for prevention of venous thromboembolism in total hip arthroplasty.
Hardwick ME; Pulido PA; Colwell CW
Orthop Nurs; 2011; 30(5):312-6. PubMed ID: 21934585
[TBL] [Abstract][Full Text] [Related]
18. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
19. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]